Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma

Sarcoma

Volumn 2011, Issue , 2011, Pages

  Linardic, Corinne M ^a   Crose, Lisa E S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEDIRANIB; CIXUTUMUMAB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE P60; PROTEIN TYROSINE KINASE; RAF PROTEIN; RAPAMYCIN; ROBATUMUMAB; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN C RECEPTOR; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CHILDHOOD CANCER; DRUG TARGETING; HUMAN; METASTASIS; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; RECURRENT CANCER; REVIEW; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR XENOGRAFT; UNSPECIFIED SIDE EFFECT;

EID: 79952234603     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2011/756982     Document Type: Review

References (105)

1. Parham D. M., Pathologic classification of rhabdomyosarcomas and correlations with molecular s (Pubitemid 32448750)
2. Ognjanovic S., Linabery A. M., Charbonneau B., Ross J. A., Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 19752005 Cancer 2009 115 18 4218 4226
3. Sumegi J., Streblow R., Frayer R. W., Cin P. D., Rosenberg A., Meloni-Ehrig A., Bridge J. A., Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family Genes Chromosomes and Cancer 2010 49 3 224 236
4. Sorensen P. H. B., Lynch J. C., Qualman S. J., Tirabosco R., Lim J. F., Maurer H. M., Bridge J. A., Crist W. M., Tricke T. J., Barr F. G., PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group Journal of Clinical Oncology 2002 20 11 2672 2679 (Pubitemid 34575640)
5. Davicioni E., Anderson J. R., Buckley J. D., Meyer W. H., Triche T. J., Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children's oncology group Journal of Clinical Oncology 2010 28 7 1240 1246
6. Williamson D., Missiaglia E., de Reynies A., Pierron G., Thuille B., Palenzuela G., Thway K., Orbach D., La M., Frneaux P., Pritchard-Jones K., Oberlin O., Shipley J., Delattre O., Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma Journal of Clinical Oncology 2010 28 13 2151 2158
7. McDowell H. P., Update on childhood rhabdomyosarcoma Archives of Disease in Childhood 2003 88 4 354 357 (Pubitemid 36398983)
8. Liu J. P., Baker J., Perkins A. S., Robertson E. J., Efstratiadis A., Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r) Cell 1993 75 1 59 72 (Pubitemid 23306021)
9. Florini J. R., Ewton D. Z., Coolican S. A., Growth hormone and the insulin-like growth factor system in myogenesis Endocrine Reviews 1996 17 5 481 517 (Pubitemid 26346639)
10. Dupont J., Holzenberger M., Biology of insulin-like growth factors in development Birth Defects Research Part C 2003 69 4 257 271 (Pubitemid 38076451)
11. Scott J., Cowell J., Robertson M. E., Insulin-like growth factor-II gene expression in Wilms' tumour and embryonic tissues Nature 1985 317 6034 260 262 (Pubitemid 16246503)
12. El-Badry O. M., Minniti C., Kohn E. C., Houghton P. J., Daughaday W. H., Helman L. J., Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors Cell Growth and Differentiation 1990 1 7 325 331
13. Zhan S., Shapiro D. N., Helman L. J., Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma Journal of Clinical Investigation 1994 94 1 445 448 (Pubitemid 24218124)
14. Pedone P. V., Tirabosco R., Cavazzana A. O., Ungaro P., Basso G., Luksch R., Carli M., Bruni C. B., Frunzio R., Riccio A., Mono- and bi-allelic expression of insulin-like growth factor II gene in human muscle tumors Human Molecular Genetics 1994 3 7 1117 1121 (Pubitemid 24211956)
15. Cao L., Yu Y., Bilke S., Walker R. L., Mayeenuddin L. H., Azorsa D. O., Yang F., Pineda M., Helman L. J., Meltzer P. S., Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer Cancer Research 2010 70 16 6497 6508
16. Cao L., Yu Y., Darko I., Currier D., Mayeenuddin L. H., Wan X., Khanna C., Helman L. J., Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody Cancer Research 2008 68 19 8039 8048
17. Dilling M. B., Dias P., Shapiro D. N., Germain G. S., Johnson R. K., Houghton P. J., Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor Cancer Research 1994 54 4 903 907 (Pubitemid 24085438)
18. Shapiro D. N., Jones B. G., Shapiro L. H., Dias P., Houghton P. J., Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma Journal of Clinical Investigation 1994 94 3 1235 1242 (Pubitemid 24286468)
19. Kalebic T., Tsokos M., Helman L. J., In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34(cdc2) Cancer Research 1994 54 21 5531 5534
20. Kalebic T., Blakesley V., Slade C., Plasschaert S., Leroith D., Lee Helman J., Expression of a kinase-deficient IGF-I-R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing a wild type IGF-I-R International Journal of Cancer 1998 76 2 223 227 (Pubitemid 28180376)
21. Maloney E. K., McLaughlin J. L., Dagdigian N. E., Garrett L. M., Connors K. M., Zhou X. M., Blttler W. A., Chittenden T., Singh R., An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation Cancer Research 2003 63 16 5073 5083 (Pubitemid 37022647)
22. Scotlandi K., Manara M. C., Nicoletti G., Lollini P. L., Lukas S., Benini S., Croci S., Perdichizzi S., Zambelli D., Serra M., Garca-Echeverra C., Hofmann F., Picci P., Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors Cancer Research 2005 65 9 3868 3876 (Pubitemid 40616368)
23. Carboni J. M., Wittman M., Yang Z., Lee F., Greer A., Hurlburt W., Hillerman S., Cao C., Cantor G. H., Dell-John J., Chen C., Discenza L., Menard K., Li A., Trainor G., Vyas D., Kramer R., Attar R. M., Gottardis M. M., BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR Molecular Cancer Therapeutics 2009 8 12 3341 3349
24. Huang F., Greer A., Hurlburt W., Han X., Hafezi R., Wittenberg G. M., Reeves K., Chen J., Robinson D., Li A., Lee F. Y., Gottardis M. M., Clark E., Helman L., Attar R. M., Dongre A., Carboni J. M., The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors Cancer Research 2009 69 1 161 170
25. Houghton P. J., Morton C. L., Gorlick R., Kolb E. A., Keir S. T., Reynolds C. P., Kang M. H., Maris J. M., Wu J., Smith M. A., Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the pediatric preclinical testing program Pediatric Blood and Cancer 2010 54 7 921 926
26. Hosoi H., Dilling M. B., Shikata T., Liu L. N., Shu L., Ashmun R. A., Germain G. S., Abraham R. T., Houghton P. J., Rapamycin causes poorly reversible inhibition of mTOR and induces p53- independent apoptosis in human rhabdomyosarcoma cells Cancer Research 1999 59 4 886 894 (Pubitemid 29086744)
27. Harrington L. S., Findlay G. M., Gray A., Tolkacheva T., Wigfield S., Rebholz H., Barnett J., Leslie N. R., Cheng S., Shepherd P. R., Gout I., Downes C. P., Lamb R. F., The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins Journal of Cell Biology 2004 166 2 213 223 (Pubitemid 38988774)
28. Kurmasheva R. T., Dudkin L., Billups C., Debelenko L. V., Morton C. L., Houghton P. J., The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma Cancer Research 2009 69 19 7662 7671
29. Wan X., Harkavy B., Shen N., Grohar P., Helman L. J., Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism Oncogene 2007 26 13 1932 1940 (Pubitemid 46474636)
30. Bladt F., Riethmacher D., Isenmann S., Aguzzi A., Birchmeier C., Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud Nature 1995 376 6543 768 771
31. Gal-Levi R., Leshem Y., Aoki S., Nakamura T., Halevy O., Hepatocyte growth factor plays a dual role in regulating skeletal muscle satellite cell proliferation and differentiation Biochimica et Biophysica Acta 1998 1402 1 39 51 (Pubitemid 28122383)
32. Anastasi S., Giordano S., Sthandier O., Gambarotta G., Maione R., Comoglio P., Amati P., A natural hepatocyte growth factor/scatter factor autocrine loop in myoblast cells and the effect of the constitutive met kinase activation on myogenic differentiation Journal of Cell Biology 1997 137 5 1057 1068 (Pubitemid 27251041)
33. Jankowski K., Kucia M., Wysoczynski M., Reca R., Zhao D., Trzyna E., Trent J., Peiper S., Zembala M., Ratajczak J., Houghton P., Janowska-Wieczorek A., Ratajczak M. Z., Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy Cancer Research 2003 63 22 7926 7935 (Pubitemid 37466729)
34. Ferracini R., Olivero M., Di Renzo M. F., Martano M., De Giovanni C., Nanni P., Basso G., Scotlandi K., Lollini P. L., Comoglio P. M., Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas Oncogene 1996 12 8 1697 1705 (Pubitemid 26146294)
35. Lukasiewicz E., Miekus K., Kijowski J., Drabik G., Wilusz M., Bobis-Wozowicz S., Majka M., Inhibition of rhabdomyosarcoma's metastatic behavior through downregulation of MET receptor signaling Folia Histochemica et Cytobiologica 2009 47 3 485 489
36. Lesko E., Gozdzik J., Kijowski J., Jenner B., Wiecha O., Majka M., HSP90 antagonist, geldanamycin, inhibits proliferation, induces apoptosis and blocks migration of rhabdomyosarcoma cells in vitro and seeding into bone marrow in vivo Anti-Cancer Drugs 2007 18 10 1173 1181 (Pubitemid 47480742)
37. Diomedi-Camassei F., McDowell H. P., De loris M. A., Uccini S., Altavista P., Raschell G., Vitali R., Mannarino O., De Sio L., Cozzi D. A., Donfrancesco A., Inserra A., Callea F., Dominici C., Clinical significance of CXC chemokine receptor-4 and c-Met in childhood rhabdomyosarcoma Clinical Cancer Research 2008 14 13 4119 4127
38. Bober E., Franz T., Arnold H. H., Gruss P., Tremblay P., Pax-3 is required for the development of limb muscles: a possible role for the migration of dermomyotomal muscle progenitor cells Development 1994 120 3 603 612 (Pubitemid 24071202)
39. Epstein J. A., Shapiro D. N., Cheng J., Lam P. Y. P., Maas R. L., PAX3 modulates expression of the c-met receptor during limb muscle development Proceedings of the National Academy of Sciences of the United States of America 1996 93 9 4213 4218 (Pubitemid 26144265)
40. Ginsberg J. P., Davis R. J., Bennicelli J. L., Nauta L. E., Barr F. G., Up-regulation of MET but not neural cell adhesion molecule expression by the PAX3 -FKHR fusion protein in alveolar rhabdomyosarcoma Cancer Research 1998 58 16 3542 3546 (Pubitemid 28376547)
41. Tiffin N., Williams R. D., Shipley J., Pritchard-Jones K., PAX7 expression in embryonal rhabdomyosarcoma suggests an origin in muscle satellite cells British Journal of Cancer 2003 89 2 327 332 (Pubitemid 36976324)
42. Taulli R., Scuoppo C., Bersani F., Accornero P., Forni P. E., Miretti S., Grinza A., Allegra P., Schmitt-Ney M., Crepaldi T., Ponzetto C., Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma Cancer Research 2006 66 9 4742 4749
43. Takayama H., Larochelle W. J., Sharp R., Otsuka T., Kriebel P., Anver M., Aaronson S. A., Merlino G., Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor Proceedings of the National Academy of Sciences of the United States of America 1997 94 2 701 706
44. Sharp R., Recio J. A., Jhappan C., Otsuka T., Liu S., Yu Y., Liu W., Anver M., Navid F., Helman L. J., DePinho R. A., Merlino G., Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis Nature Medicine 2002 8 11 1276 1280 (Pubitemid 35373560)
45. Relaix F., Polimeni M., Rocancourt D., Ponzetto C., Schfer B. W., Buckingham M., The transcriptional activator PAX3-FKHR rescues the defects of PAX3 mutant mice but induces a myogenic gain-of-function phenotype with ligand-independent activation of Met signaling in vivo Genes and Development 2003 17 23 2950 2965 (Pubitemid 37523158)
46. Keller C., Arenkiel B. R., Coffin C. M., El-Bardeesy N., DePinho R. A., Capecchi M. R., Alveolar rhabdomyosarcomas in conditional PAX3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function Genes and Development 2004 18 21 2614 2626 (Pubitemid 39453101)
47. Sithanandam G., Anderson L. M., The ERBB3 receptor in cancer and cancer gene therapy Cancer Gene Therapy 2008 15 7 413 448 (Pubitemid 351822188)
48. Horikawa M., Higashiyama S., Nomura S., Kitamura Y., Ishikawa M., Taniguchi N., Upregulation of endogenous heparin-binding EGF-like growth factor and its role as a survival factor in skeletal myotubes FEBS Letters 1999 459 1 100 104 (Pubitemid 29447663)
49. Harari P. M., Epidermal growth factor receptor inhibition strategies in oncology Endocrine-Related Cancer 2004 11 4 689 708 (Pubitemid 40065545)
50. Maris J. M., Courtright J., Houghton P. J., Morton C. L., Gorlick R., Kolb E. A., Lock R., Tajbakhsh M., Reynolds C. P., Keir S. T., Wu J., Smith M. A., Initial testing of the VEGFR inhibitor AZD2171 by the Pediatric Preclinical Testing Program Pediatric Blood and Cancer 2008 50 3 581 587 (Pubitemid 351155829)
51. De Giovanni C., Melani C., Nanni P., Landuzzi L., Nicoletti G., Frabetti F., Griffoni C., Colombo M. P., Lollini P. L., Redundancy of autocrine loops in human rhabdomyosarcoma cells: induction of differentiation by suramin British Journal of Cancer 1995 72 5 1224 1229
52. Ricci C., Landuzzi L., Rossi I., De Giovanni C., Nicoletti G., Astolfi A., Pupa S., Menard S., Scotlandi K., Nanni P., Loluni P. L., Expression of HER/erbB family of receptor tyrosine kinases and induction of differentiation by glial growth factor 2 in human rhabdomyosarcoma cells International Journal of Cancer 2000 87 1 29 36 (Pubitemid 30368412)
53. Armistead P. M., Salganick J., Roh J. S., Steinert D. M., Patel S., Munsell M., El-Naggar A. K., Benjamin R. S., Zhang W., Trent J. C., Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma: correlation with overall survival in 105 patients Cancer 2007 110 10 2293 2303 (Pubitemid 350100752)
54. Grass B., Wachtel M., Behnke S., Leuschner I., Niggli F. K., Schfer B. W., Immunohistochemical detection of EGFR, fibrillin-2, P-cadherin and AP2 as biomarkers for rhabdomyosarcoma diagnostics Histopathology 2009 54 7 873 879
55. Ganti R., Skapek S. X., Zhang J., Fuller C. E., Wu J., Billups C. A., Breitfeld P. P., Dalton J. D., Meyer W. H., Khoury J. D., Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma Modern Pathology 2006 19 9 1213 1220 (Pubitemid 44268191)
56. Wachtel M., Runge T., Leuschner I., Stegmaier S., Koscielniak E., Treuner J., Odermatt B., Behnke S., Niggli F. K., Schfer B. W., Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry Journal of Clinical Oncology 2006 24 5 816 822 (Pubitemid 46622049)
57. de Andrade C. R., Takahama Junior A., Nishimoto I. N., Kowalski L. P., Lopes M. A., Rhabdomyosarcoma of the head and neck: a clinicopathological and immunohistochemical analysis of 29 cases Brazilian Dental Journal 2010 21 1 68 73
58. De Giovanni C., Landuzzi L., Frabetti F., Nicoletti G., Griffoni C., Rossi I., Mazzotti M., Scotto L., Nanni P., Lollini P. L., Antisense epidermal growth factor receptor transfection impairs the proliferative ability of human rhabdomyosarcoma cells Cancer Research 1996 56 17 3898 3901 (Pubitemid 26284736)
59. Nanni P., Nicoletti G., De Giovanni C., Croci S., Astolfi A., Landuzzi L., Di Carlo E., Iezzi M., Musiani P., Lollini P. L., Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice Cancer Research 2003 63 11 2728 2732 (Pubitemid 36667140)
60. Croci S., Nicoletti G., Landuzzi L., De Giovanni C., Astolfi A., Marini C., Di Carlo E., Musiani P., Forni G., Nanni P., Lollini P. L., Immunological prevention of a multigene cancer syndrome Cancer Research 2004 64 22 8428 8434 (Pubitemid 39491783)
61. Freeman B. B. III, Daw N. C., Geyer J. R., Furman W. L., Stewart C. F., Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients Cancer Investigation 2006 24 3 310 317
62. Jakacki R. I., Hamilton M., Gilbertson R. J., Blaney S. M., Tersak J., Krailo M. D., Ingle A. M., Voss S. D., Dancey J. E., Adamson P. C., Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a children's oncology group phase I consortium study Journal of Clinical Oncology 2008 26 30 4921 4927
63. Andrae J., Gallini R., Betsholtz C., Role of platelet-derived growth factors in physiology and medicine Genes and Development 2008 22 10 1276 1312 (Pubitemid 351717519)
64. Fiaschi T., Chiarugi P., Buricchi F., Giannoni E., Taddei M. L., Magnelli L., Cozzi G., Raugei G., Ramponi G., Down-regulation of platelet-derived growth factor receptor signaling during myogenesis Cellular and Molecular Life Sciences 2003 60 12 2721 2735 (Pubitemid 38041372)
65. Webb S. E., Lee K. K. H., Effect of platelet-derived growth factor isoforms on the migration of mouse embryo limb myogenic cells International Journal of Developmental Biology 1997 41 4 597 605 (Pubitemid 27368581)
66. Yablonka-Reuveni Z., Balestreri T. M., Bowen-Pope D. F., Regulation of proliferation and differentiation of myoblasts derived from adult mouse skeletal muscle by specific isoforms of PDGF Journal of Cell Biology 1990 111 4 1623 1629
67. Malik R., Gope M., Womer R. B., Nagashunmugam T., Margolin J. F., Basu A., Scher C. D., Structure and expression of the -platelet-derived growth factor receptor gene in human tumor cell lines Cancer Research 1991 51 20 5626 5631
68. McDowell H. P., Meco D., Riccardi A., Tanno B., Berardi A. C., Raschell G., Riccardi R., Dominici C., Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models International Journal of Cancer 2007 120 5 1141 1149 (Pubitemid 46214319)
69. McDermott U., Ames R. Y., Iafrate A. J., Maheswaran S., Stubbs H., Greninger P., Mccutcheon K., Milano R., Tam A., Lee D. Y., Lucien L., Brannigan B. W., Ulkus L. E., Ma X. J., Erlander M. G., Haber D. A., Sharma S. V., Settleman J., Ligand-dependent platelet-derived growth factor receptor (PDGFR)- activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors Cancer Research 2009 69 9 3937 3946
70. Epstein J. A., Song B., Lakkis M., Wang C., Tumor-specific PAX3 -FKHR transcription factor, but not PAX3, activates the platelet-derived growth factor alpha receptor Molecular and Cellular Biology 1998 18 7 4118 4130 (Pubitemid 28287935)
71. Taniguchi E., Nishijo K., McCleish A. T., Michalek J. E., Grayson M. H., Infante A. J., Abboud H. E., Legallo R. D., Qualman S. J., Rubin B. P., Keller C., PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma Oncogene 2008 27 51 6550 6560
72. Blandford M. C., Barr F. G., Lynch J. C., Randall R. L., Qualman S. J., Keller C., Rhabdomyosarcomas utilize developmental, myogenic growth factors for disease advantage: a report from the children's oncology group Pediatric Blood and Cancer 2006 46 3 329 338 (Pubitemid 43201849)
73. Chugh R., Wathen J. K., Maki R. G., Benjamin R. S., Patel S. R., Myers P. A., Priebat D. A., Reinke D. K., Thomas D. G., Keohan M. L., Samuels B. L., Baker L. H., Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model Journal of Clinical Oncology 2009 27 19 3148 3153
74. Carmeliet P., Jain R. K., Angiogenesis in cancer and other diseases Nature 2000 407 6801 249 257
75. Germani A., Di Carlo A., Mangoni A., Straino S., Giacinti C., Turrini P., Biglioli P., Capogrossi M. C., Vascular endothelial growth factor modulates skeletal myoblast function American Journal of Pathology 2003 163 4 1417 1428 (Pubitemid 37175089)
76. Gee M. F. W., Tsuchida R., Eichler-Jonsson C., Das B., Baruchel S., Malkin D., Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid Oncogene 2005 24 54 8025 8037 (Pubitemid 41746746)
77. Kurmasheva R. T., Harwood F. C., Houghton P. J., Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors Molecular Cancer Therapeutics 2007 6 5 1620 1628 (Pubitemid 46954029)
78. Brekken R. A., Overholser J. P., Stastny V. A., Waltenberger J., Minna J. D., Thorpe P. E., Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice Cancer Research 2000 60 18 5117 5124
79. Gerber H. P., Kowalski J., Sherman D., Eberhard D. A., Ferrara N., Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor Cancer Research 2000 60 22 6253 6258
80. Holash J., Davis S., Papadopoulos N., Croll S. D., Ho L., Russell M., Boland P., Leidich R., Hylton D., Burova E., Ioffe E., Huang T., Radziejewski C., Bailey K., Fandl J. P., Daly T., Wiegand S. J., Yancopoulos G. D., Rudge J. S., VEGF-Trap: a VEGF blocker with potent antitumor effects Proceedings of the National Academy of Sciences of the United States of America 2002 99 17 11393 11398 (Pubitemid 34920936)
81. Rich J. N., Sathornsumetee S., Keir S. T., Kieran M. W., Laforme A., Kaipainen A., McLendon R. E., Graner M. W., Rasheed B. K. A., Wang L., Reardon D. A., Ryan A. J., Wheeler C., Dimery I., Bigner D. D., Friedman H. S., ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors Clinical Cancer Research 2005 11 22 8145 8157 (Pubitemid 41698759)
82. Tsuchida R., Das B., Yeger H., Koren G., Shibuya M., Thorner P. S., Baruchel S., Malkin D., Cisplatin treatment increases survival and expansion of a highly tumorigenic side-population fraction by upregulating VEGF/Flt1 autocrine signaling Oncogene 2008 27 28 3923 3934 (Pubitemid 351913641)
83. Eswarakumar V. P., Lax I., Schlessinger J., Cellular signaling by fibroblast growth factor receptors Cytokine and Growth Factor Reviews 2005 16 2 139 149 (Pubitemid 40616112)
84. Zhao PO., Caretti G., Mitchell S., McKeehan W. L., Boskey A. L., Pachman L. M., Sartorelli V., Hoffman E. P., Fgfr4 is required for effective muscle regeneration in vivo delineation of a MyoD-Tead2-Fgfr4 transcriptional pathway Journal of Biological Chemistry 2006 281 1 429 438 (Pubitemid 43671204)
85. Marics I., Padilla F., Guillemot J. F., Scaal M., Marcelle C., FGFR4 signaling is a necessary step in limb muscle differentiation Development 2002 129 19 4559 4569 (Pubitemid 35203737)
86. Pizette S., Coulier F., Birnbaum D., Delapeyrire O., FGF6 modulates the expression of fibroblast growth factor receptors and myogenic genes in muscle cells Experimental Cell Research 1996 224 1 143 151 (Pubitemid 26116898)
87. Goldstein M., Meller I., Orr-Urtreger A., FGFR1 over-expression in primary rhabdomyosarcoma tumors is associated with hypomethylation of a 5′ CpG island and abnormal expression of the AKT1, NOG, and BMP4 genes Genes Chromosomes and Cancer 2007 46 11 1028 1038 (Pubitemid 47502842)
88. Hirotsu M., Setoguchi T., Matsunoshita Y., Sasaki H., Nagao H., Gao H., Sugimura K., Komiya S., Tumour formation by single fibroblast growth factor receptor 3-positive rhabdomyosarcoma-initiating cells British Journal of Cancer 2009 101 12 2030 2037
89. Schweigerer L., Neufeld G., Mergia A., Basic fibroblast growth factor in human rhabdomyosarcoma cells: implications for the proliferation and neovascularization of myoblast-derived tumors Proceedings of the National Academy of Sciences of the United States of America 1987 84 3 842 846 (Pubitemid 17033903)
90. Yu S. J., Zheng L., Ladanyi M., Asa S. L., Ezzat S., Sp1-mediated transcriptional control of fibroblast growth factor receptor 4 in sarcomas of skeletal muscle lineage Clinical Cancer Research 2004 10 19 6750 6758 (Pubitemid 39346573)
91. Khan J., Wei J. S., Ringner M., Saal L. H., Ladanyi M., Westermann F., Berthold F., Schwab M., Antonescu C. R., Peterson C., Meltzer P. S., Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks Nature Medicine 2001 7 6 673 679 (Pubitemid 32588022)
92. Taylor J. G., Cheuk A. T., Tsang P. S., Chung J. Y., Song Y. K., Desai K., Yu Y., Chen Q. R., Shah K., Youngblood V., Fang J., Su Y. K., Yeung C., Helman L. J., Mendoza A., Ngo VU., Staudt L. M., Wei J. S., Khanna C., Catchpoole D., Qualman S. J., Hewitt S. M., Merlino G., Chanock S. J., Khan J., Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models Journal of Clinical Investigation 2009 119 11 3395 3407
93. Barber T. D., Barber M. C., Tomescu O., Barr F. G., Ruben S., Friedman T. B., Identification of target genes regulated by PAX3 and PAX3-FKHR in embryogenesis and alveolar rhabdomyosarcoma Genomics 2002 79 3 278 284 (Pubitemid 34211935)
94. Chen Y., Takita J., Mizuguchi M., Tanaka K., Ida K., Koh K., Igarashi T., Hanada R., Tanaka Y., Park M. J., Hayashi Y., Mutation and expression analyses of the MET and CDKN2A in rhabdomyosarcoma with emphasis on MET overexpression Genes Chromosomes and Cancer 2007 46 4 348 358 (Pubitemid 46411326)
95. Werner H., Karnieli E., Rauscher F. J., LeRoith D., Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene Proceedings of the National Academy of Sciences of the United States of America 1996 93 16 8318 8323 (Pubitemid 26269555)
96. Hak K. K., Yong S. L., Sivaprasad U., Malhotra A., Dutta A., Muscle-specific microRNA miR-206 promotes muscle differentiation Journal of Cell Biology 2006 174 5 677 687 (Pubitemid 44306724)
97. Taulli R., Bersani F., Foglizzo V., Linari A., Vigna E., Ladanyi M., Tuschl T., Ponzetto C., The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation Journal of Clinical Investigation 2009 119 8 2366 2378
98. Yan D., Dong X. D., Chen X., Wang L., Lu C., Wang J., Qu J., Tu L., MicroRNA-1/206 targets c-met and inhibits rhabdomyosarcoma development Journal of Biological Chemistry 2009 284 43 29596 29604
99. Weinstein I. B., Joe A., Oncogene addiction Cancer Research 2008 68 9 3077 3080
100. Lynch T. J., Bell D. W., Sordella R., Gurubhagavatula S., Okimoto R. A., Brannigan B. W., Harris P. L., Haserlat S. M., Supko J. G., Haluska F. G., Louis D. N., Christiani D. C., Settleman J., Haber D. A., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib New England Journal of Medicine 2004 350 21 2129 2139 (Pubitemid 38637993)
101. Keir S. T., Maris J. M., Lock R., Kolb E. A., Gorlick R., Carol H., Morton C. L., Reynolds C. P., Kang M. H., Watkins A., Houghton P. J., Smith M. A., Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program Pediatric Blood and Cancer 2010 55 6 1126 1133
102. Herrmann D., Seitz G., Warmann S. W., Bonin M., Fuchs J., Armeanu-Ebinger S., Cetuximab promotes immunotoxicity against rhabdomyosarcoma in vitro Journal of Immunotherapy 2010 33 3 279 286
103. Sierra J. R., Cepero V., Giordano S., Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy Molecular Cancer 2010 9, article no.75
104. Hanahan D., Weinberg R. A., The hallmarks of cancer Cell 2000 100 1 57 70 (Pubitemid 30046295)
105. Negrini S., Gorgoulis V. G., Halazonetis T. D., Genomic instability an evolving hallmark of cancer Nature Reviews Molecular Cell Biology 2010 11 3 220 22